July 6, 2020 / 8:21 PM / a month ago

BRIEF-Otonomy Reports Positive Top-Line Results From Phase 1/2 Clinical Trial Of Oto-313 In Patients With Tinnitus

July 6 (Reuters) - Otonomy Inc:

* OTONOMY REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 1/2 CLINICAL TRIAL OF OTO-313 IN PATIENTS WITH TINNITUS

* OTONOMY INC - OTO-313 DEMONSTRATED A HIGHER PROPORTION OF RESPONDERS THAN PLACEBO

* OTONOMY INC - PLANS TO ADVANCE OTO-313 TO FULL PHASE 2 DEVELOPMENT IN TINNITUS

* OTONOMY INC - OTO-313 WAS WELL-TOLERATED WITH LOWER INCIDENCE OF ADVERSE EVENTS THAN PLACEBO GROUP

* OTONOMY - TRIAL ACHIEVED OBJECTIVES BY SHOWING POSITIVE CLINICAL SIGNAL FOR OTO-313 BASED ON TFI RESPONDER ANALYSIS, WITH FAVORABLE SAFETY PROFILE

* OTONOMY INC - RESULTS FOR OTO-413 PHASE 1/2 TRIAL EXPECTED IN Q4 OF 2020

* OTONOMY INC - RESULTS FROM PHASE 3 TRIAL OF OTIVIDEX IN MÉNIÈRE’S DISEASE EXPECTED IN Q1 OF 2021 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below